TCF7L2 Pharmaceutical composition for prevention and treatment of non-alcoholic fatty liver disease comprising transcription factor 7-like 2 as effective component

摘要

The present invention relates to a pharmaceutical composition comprising TCF7L2 protein or gene as an effective component for preventing or treating non-alcoholic fatty liver induced by high-carbohydrate diet. According to the present invention, in a liver-specific TCF7L2 knockout animal model, fatty liver was promoted through de novo lipogenesis induced by high-carbohydrate diet, while the overexpression of TCF7L2 under a condition similar to high-carbohydrate diet decreased the genes relating to increased de novo lipogenesis. However, since there is almost no change in terms of the effect due to regulation of TCF7L2 expression in fatty liver induced by high-fat diet, the composition of the present invention comprising TCF7L2 protein or gene as an effective component can be beneficially used as a therapeutic agent for non-alcoholic fatty liver induced by high-carbohydrate diet or induced by de novo lipogenesis induced by high-carbohydrate diet.